Other Indications: Glaucoma
Glaucoma is a progressive, age-related disease and the leading cause of irreversible vision loss, affecting 60 million people worldwide, including 3 million people in the United States. Glaucoma is the result of increased intraocular pressure (IOP) due to a buildup of aqueous humor in the eye. Sustained elevated IOP damages the optic nerve, resulting in loss of vision and blindness. There are currently five classes of approved glaucoma medications. U.S. spending on glaucoma medications in 2016 totaled $2.8 billion, yet almost half of patients in treatment for glaucoma do not reach normal IOP goals. Second-line treatments, especially for patients in normotensive range, are needed to decrease patients’ IOP levels. A potential mechanism of action of IOP lowering is through episcleral venous pressure.
We are looking for a partner for this program for continued Phase 2 development.